CETP Inhibition: Does the Future Look Promising?
Based on epidemiologic studies conducted throughout the world, it is established that there is an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and risk for coronary artery disease (CAD). The incidence of low HDL-C is high and increasing throughout the world. A variety of pharmacologic approaches are being developed to therapeutically modulate serum levels of HDL-C. One controversial approach to this is the use of molecules that inhibit the activity of cholesteryl ester transfer protein (CETP), an enzyme involved in neutral lipid transfer between lipoproteins. The inhibition of CETP can lead to substantial elevations in HDL-C. Based on a number of considerations, including the complex relationship between loss of function mutations in CETP and risk for CAD and the clinical experience with torcetrapib, it is difficult to predict if CETP inhibition will be associated with reductions in rates of atherosclerosis disease progression and risk for cardiovascular events.
KeywordsApolipoprotein A-IApolipoprotein BAtherosclerosisCholesterolCholesteryl ester transfer proteinCETPCoronary artery diseaseHigh-density lipoproteinLow-density lipoprotein receptorReverse cholesterol transportPolymorphismScavenger receptor BIVery low density lipoprotein
Clinical Trial Acronyms
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes
Dalcetrapib HDL Evaluation, Atherosclerosis, and Reverse Cholesterol Transport Program
Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib
Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events
Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation
Treatment of High-Density Lipoprotein to Reduce the Incidence of Vascular Events
Rating Atherosclerotic Disease Change by Imaging with a New CEPT Inhibitor
Regression Growth Evaluation Statin Study
- REVEAL HPS-3 TIMI-55
Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification